A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer

NCT02314117 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

645

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Ramucirumab
DRUG: Capecitabine
DRUG: Cisplatin
DRUG: Placebo
DRUG: Fluorouracil

Sponsor

Eli Lilly and Company